{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:05:51Z","timestamp":1772643951258,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11864-018-0597-y","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T02:34:43Z","timestamp":1543286083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis"],"prefix":"10.1007","volume":"19","author":[{"given":"Zehua","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"597_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra M, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683\u201391.","journal-title":"Gut"},{"key":"597_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2017.01.01","volume":"29","author":"W Chen","year":"2017","unstructured":"Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017;29:1\u201310.","journal-title":"Chin J Cancer Res"},{"key":"597_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10620-016-4362-4","volume":"62","author":"J Zhu","year":"2016","unstructured":"Zhu J, Tan Z, Hollis-Hansen K, Zhang Y, Yu C, Li Y. Epidemiological trends in colorectal cancer in China: an ecological study. Dig Dis Sci. 2016;62:235\u201343.","journal-title":"Dig Dis Sci"},{"key":"597_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"\u2022 Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29:44\u201370. The reference provides different treatment guidelines emphasizing the role of IV 5-FU in the management of CRC and thus highlighting the implications of this meta-analysis.","journal-title":"Ann Oncol"},{"key":"597_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","volume":"15","author":"AB Benson","year":"2017","unstructured":"\u2022 Benson AB, Venook AP, Cederquist L, Chan E, Chen Y-J, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:370\u201398. The reference provides different treatment guidelines emphasizing the role of IV 5-FU in the management of CRC and thus highlighting the implications of this meta-analysis.","journal-title":"J Natl Compr Cancer Netw"},{"key":"597_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Cutsem Van","year":"2016","unstructured":"\u2022 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422. The reference provides different treatment guidelines emphasizing the role of IV 5-FU in the management of CRC and thus highlighting the implications of this meta-analysis.","journal-title":"Ann Oncol"},{"key":"597_CR7","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109\u201316.","journal-title":"J Clin Oncol"},{"key":"597_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143\u201352.","journal-title":"Lancet"},{"key":"597_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.clcc.2011.06.012","volume":"10","author":"AS Lucas","year":"2011","unstructured":"Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10:238\u201344.","journal-title":"Clin Colorectal Cancer"},{"key":"597_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1200\/JCO.1997.15.1.246","volume":"15","author":"MJ O'Connell","year":"1997","unstructured":"O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246\u201350.","journal-title":"J Clin Oncol"},{"key":"597_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.1992.10.6.904","volume":"10","author":"Nordic Gastrointestinal Tumor Adjuvant Therapy Group","year":"1992","unstructured":"Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10:904\u201311.","journal-title":"J Clin Oncol"},{"key":"597_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","volume":"306","author":"W Scheithauer","year":"1993","unstructured":"Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752\u20135.","journal-title":"Br Med J"},{"key":"597_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","volume":"16","author":"Meta-analysis Group in Cancer","year":"1998","unstructured":"Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301\u20138.","journal-title":"J Clin Oncol"},{"key":"597_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_4-3","volume":"6","author":"P Hoff","year":"2001","unstructured":"Hoff P, Cassidy J, Schmollc H. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist. 2001;6:3\u201311.","journal-title":"Oncologist"},{"key":"597_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Sch\u00fcller","year":"2000","unstructured":"Sch\u00fcller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"597_CR16","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Cutsem Van","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"597_CR17","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282\u201392.","journal-title":"J Clin Oncol"},{"key":"597_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","volume":"19","author":"ML Rothenberg","year":"2008","unstructured":"Rothenberg ML, Cox JV, Butts C, Navarro M, Bang Y-J, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19:1720\u20136.","journal-title":"Ann Oncol"},{"key":"597_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ijc.25369","volume":"128","author":"M Ducreux","year":"2011","unstructured":"Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128:682\u201390.","journal-title":"Int J Cancer"},{"key":"597_CR20","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R. A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006\u201312.","journal-title":"J Clin Oncol"},{"key":"597_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bjc.2012.384","volume":"107","author":"A Madi","year":"2012","unstructured":"Madi A, Fisher D, Wilson RH, Adams RA, Meade AM, Kenny SL, et al. Oxaliplatin\/capecitabine vs oxaliplatin\/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer. 2012;107:1037\u201343.","journal-title":"Br J Cancer"},{"key":"597_CR22","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"E D\u00edaz-Rubio","year":"2007","unstructured":"D\u00edaz-Rubio E, Tabernero J, G\u00f3mez-Espa\u00f1a A, Massut\u00ed B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol. 2007;25:4224\u201330.","journal-title":"J Clin Oncol"},{"key":"597_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1471-2407-12-271","volume":"12","author":"D Pectasides","year":"2012","unstructured":"Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic cooperative oncology group phase III trial with collateral biomarker analysis. BMC Cancer. 2012;12:271\u201381.","journal-title":"BMC Cancer"},{"key":"597_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2407-9-120","volume":"9","author":"E Skof","year":"2009","unstructured":"Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU\/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009;9:120\u20139.","journal-title":"BMC Cancer"},{"key":"597_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bjc.2011.594","volume":"106","author":"J Souglakos","year":"2012","unstructured":"Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable\/metastatic colorectal cancer (mCRC). Br J Cancer. 2012;106:453\u20139.","journal-title":"Br J Cancer"},{"key":"597_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","volume":"49","author":"M Ducreux","year":"2013","unstructured":"Ducreux M, Adenis A, Pignon J-P, Francois E, Chauffert B, Ichante JL, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13\/0503 study). Eur J Cancer. 2013;49:1236\u201345.","journal-title":"Eur J Cancer"},{"key":"597_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bjc.2011.201","volume":"105","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105:58\u201364.","journal-title":"Br J Cancer"},{"key":"597_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/annonc\/mdm544","volume":"19","author":"C-H Kohne","year":"2008","unstructured":"Kohne C-H, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008;19:920\u20136.","journal-title":"Ann Oncol"},{"key":"597_CR29","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","volume":"25","author":"CS Fuchs","year":"2007","unstructured":"Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779\u201386.","journal-title":"J Clin Oncol"},{"key":"597_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","volume":"13","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol. 2002;13:566\u201375.","journal-title":"Ann Oncol"},{"key":"597_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008398.pub2","volume-title":"Oral versus intravenous fluoropyrimidines for colorectal cancer","author":"F Chionh","year":"2017","unstructured":"\u2022\u2022 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Hoboken: John Wiley & Sons, Ltd; 2017. [The Cochrane Collaboration] A comprehensive and detailed review and meta-analysis from the Cochrane libarary comparing oral with intravenous fluoropyrimidines for the treatment of colorectal cancer."},{"key":"597_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jgh.13845","volume":"33","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xing X, Meng F, Wang Y, Zhong D. Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis. J Gastroenterol Hepatol. 2018;33:209\u201325.","journal-title":"J Gastroenterol Hepatol"},{"key":"597_CR33","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.clcc.2017.01.009","volume":"16","author":"XC Zou","year":"2017","unstructured":"Zou XC, Wang QW, Zhang JM. Comparison of 5-FU-based and capecitabine-based neoadjuvant chemoradiotherapy in patients with rectal cancer: a meta-analysis. Clin Colorectal Cancer. 2017;16:e123\u2013e39.","journal-title":"Clin Colorectal Cancer"},{"key":"597_CR34","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1200\/JCO.2009.25.1918","volume":"27","author":"AD Sasse","year":"2009","unstructured":"Sasse AD, Sasse EC, dos Santos LV, Lima JS, Nascente CM, Saito HP. Oral fluoropyrimidines versus 5-fluorouracil for colorectal cancer: results of a systematic review and meta-analysis. J Clin Oncol. 2009;27:4111.","journal-title":"J Clin Oncol"},{"key":"597_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3816\/CCC.2010.n.036","volume":"9","author":"F Montagnani","year":"2010","unstructured":"Montagnani F, Chiriatti A, Licitra S, Aliberti C, Fiorentini G. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:243\u20137.","journal-title":"Clin Colorectal Cancer"},{"key":"597_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1463-1318.2009.01803.x","volume":"12","author":"Y Cao","year":"2009","unstructured":"Cao Y, Liao C, Tan A, Liu L, Mo Z, Gao F. Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner [cancer]: meta-analysis of six randomized trials. Color Dis. 2009;12:16\u201323.","journal-title":"Color Dis"},{"key":"597_CR37","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"597_CR38","unstructured":"Review Manager (RevMan). 5.3 ed. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2014."},{"key":"597_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"597_CR40","doi-asserted-by":"publisher","unstructured":"Deeks J, Higgins J, Altman D, on behalf of the Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Cochrane handbook of systematic reviews of interventions. 2011. \n                      https:\/\/doi.org\/10.1002\/9780470712184.ch9\n                      \n                    . Accessed 01 Sept 2018.","DOI":"10.1002\/9780470712184.ch9"},{"key":"597_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"597_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics"},{"key":"597_CR43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A Gramont de","year":"2012","unstructured":"de Gramont A, Van Cutsem E, Schmoll H-J, Tabernero J, Clarke S, Moore M, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225\u201333.","journal-title":"Lancet Oncol"},{"key":"597_CR44","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","volume":"26","author":"HS Hochster","year":"2008","unstructured":"Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523\u20139.","journal-title":"J Clin Oncol"},{"key":"597_CR45","doi-asserted-by":"publisher","first-page":"djv248","DOI":"10.1093\/jnci\/djv248","volume":"107","author":"C Allegra","year":"2015","unstructured":"Allegra C, Yothers G, O\u2019Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:djv248.","journal-title":"J Natl Cancer Inst"},{"key":"597_CR46","doi-asserted-by":"crossref","unstructured":"Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer. 2006;42:3161\u20138.","DOI":"10.1016\/j.ejca.2006.08.034"},{"key":"597_CR47","doi-asserted-by":"crossref","unstructured":"Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer.2015;15:384\u201394.","DOI":"10.1186\/s12885-015-1406-7"},{"key":"597_CR48","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","volume":"25","author":"R Porschen","year":"2007","unstructured":"Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group. J Clin Oncol. 2007;25:4217\u201323.","journal-title":"J Clin Oncol"},{"key":"597_CR49","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749\u201359.","journal-title":"Lancet"},{"key":"597_CR50","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1093\/annonc\/mdr031","volume":"22","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22:2604\u20139.","journal-title":"Ann Oncol"},{"key":"597_CR51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ejso.2012.02.002","volume":"38","author":"M Kripp","year":"2012","unstructured":"Kripp M, Wieneke J, Kienle P, Welzel G, Brade J, Horisberger K, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer\u2014impact on long-term quality of life. Eur J Surg Oncol. 2012;38:472\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"597_CR52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/bcp.12449","volume":"78","author":"R Iacovelli","year":"2014","unstructured":"Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5- fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol. 2014;78:1228\u201337.","journal-title":"Br J Clin Pharmacol"},{"key":"597_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0885-3924(99)00149-9","volume":"19","author":"S Kornblau","year":"2000","unstructured":"Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manag. 2000;19:118\u201329.","journal-title":"J Pain Symptom Manag"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-018-0597-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:24:16Z","timestamp":1574796256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-018-0597-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1007\/s11864-018-0597-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"27 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare they have conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"77"}}